The tool the administration is using to measure waste shows that expenses in Indianapolis might be low enough
not to get whacked. But the region isn’t performing so well that it’s likely to get much praise, either.
A decision by a federal judge in Indianapolis to turn back a patent challenge to Eli Lilly and Co.’s Evista marks a major
victory for the company, says an analyst who closely follows the pharmaceutical industry.
A federal judge in Indianapolis turned back a patent challenge to Eli Lilly and Co.’s drug Evista, the company announced
late yesterday.
A new group expected to develop the orthopedic implants industry in Warsaw will be able to proceed now that Indianapolis-based
Lilly Endowment Inc. is putting $7 million behind it, according to an announcement this morning.
Health insurer WellPoint said today that it may trim some more jobs as part of a push to become more efficient next year.
Eli Lilly and Co. has agreed to confidential terms to settle lawsuits brought by seven states alleging the company illegally
marketed bestselling antipsychotic drug Zyprexa, Bloomberg News reported today.
Biotechnology company Adolor Corp. said yesterday that it bought exclusive worldwide rights to Eli Lilly and Co.’s OpRA
III drug candidate, which has a range of potential uses.
Mead Johnson Nutrition plans to spend nearly $33 million at a southwestern Indiana facility where it plans to start making
powdered infant formula products.
Indianapolis-based Eli Lilly and Co. announced today that a clinical trial showed lung cancer patients treated with Lilly
drug Alimta lived about three months longer than those who received the best available care.
The Greater Indianapolis Chamber of Commerce announced its support for construction of a new Wishard Hospital and promised
to take a leadership position to help hospital leaders win voter approval for the project.
Medical equipment supplier Hill-Rom Holdings Inc. said yesterday it has begun a chief executive search to plan for the retirement
of current CEO Peter Soderberg.
The drugmaker has successfully moved experimental drugs into position to win approval by regulators. But only once in the
last four years has a new drug actually made it to market—the industry’s equivalent of getting
across the goal line.
Employees at five different companies collectively lost 805 pounds over six weeks this summer. They also
raised $805 for Big Brothers/Big Sisters of Central Indiana.
Migraines cost American employers $20 billion a year in decreased worker productivity. Such
a frequent and uncured disease stands as a huge business opportunity for the health care industry, including locally based pharmaceutical giant Eli Lilly and Co.
The launch of the orthopedics not-for-profit OrthoWorx is quite an accomplishment in Warsaw, where some of the world’s
biggest companies fight tooth-and-nail.
The Westfield City Council passed a smoking ban 7-0 last night that will prohibit smoking in most public places, including
outdoor arenas, stadiums and amphitheaters.
Since John Lechleiter was named CEO 18 months ago, he’s bet that Eli Lilly and Co. could face down its looming patent challenges
by launching innovative new medicines. Today’s announcement of 5,500 job cuts by the end of 2011 and a restructuring of the
company’s business units ups the ante on that bet, while indicating that it isn’t working yet.
Eli Lilly and Co. will cut 5,500 jobs by the end of 2011 as it tries to cut $1 billion in expenses before it loses revenue
from its bestselling drug, Zyprexa. Lilly CEO John Lechleiter said he did not know how many of those cuts would occur in central
Indiana. But with
13,600 employees working in the Indianapolis area, he acknowledged the largest chunk of reductions likely would come here.
Take the money while it’s there. That’s what a handful of insiders at WellPoint Inc. decided in
the past month as they sold off nearly 150,000 company shares for gains of more than $3 million.
Eli Lilly and Co. and its peers might be back in Congress’ sights as lawmakers hunt for more ways to cut health care
costs. A new study in the influential Health Affairs journal concludes that European drugmakers operating
in markets with pharmaceutical price controls have produced proportionally more innovations than their U.S. counterparts.
